

بسم الله الرحمن الرحيم



-C-02-50-2-





شبكة المعلومات الجامعية التوثيق الالكتروني والميكرونيلم





جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة يعيدا عن الغيار













بالرسالة صفحات لم ترد بالأصل



BIVOTY

THE ROLE OF CHROMIUM IN TREATMENT OF DIABETES MELLITUS

A Thesis Represented By

DALIA MOUSTAFA ABOU RAYA KATARI

B.Sc. of Pharmaceutical Sciences, Tanta Univesity

For The Partial Fulfillment For The Degree of Master In Pharmaceutical Sciences (Clinical Pharmacy)

SUPERVISORS

Prof. Dr.

WAGIH MAHMOUD AWARA, Ph.D.

Professor of Pharmacology and Toxicology and Vice Dean, Faculty of Pharmacy, Tanta University

Dr.

OSAMA MOHAMED IBRAHIM, Ph.D.

Assistant Professor and Chairman of Clinical Pharmacy, Dept. Faculty of Pharmacy, Tanta University Prof. Dr.

EBAA EL-SHEIKH, M.D.

Professor of Internal Medicine, Faculty of Medicine, Tanta University

Dr.

HODA ABDEL-KADER EL-BAHRAWY, Ph.D

Assistant Professor and Chairman, of Biochemistry Dept. Faculty of Pharmacy, Tanta University

CLINICAL PHARMACY DEPARTMENT FACULTY OF PHARMACY TANTA UNIVERSITY 2003

بنير النوال مراكزي

المناه المناقبة المن

(سَوْرَةُ وَالْمُحْالِدُ ، إِلَيْهُ ١٥)

First, and for most thanks to **ALLAH**, the most merciful, gracious and compassionate, to **ALLAH** everything in life is resumed.

acknowledgement

I would like to express my sincere thanks and deepest gratitude to Frof. Dr. WAGHI MAHMOUD AWARA, Professor of Pharmacology and Toxicology and Vice Dean, Faculty of Pharmacy, Tanta University for his encouragement, sustained support, export guidance, valuable instructions and suggestions throughout this work, I feel greatly honored to work under his supervision.

I would like to express my profound gratitude and deep appreciation to Frof. Dr. EBAA EL-SHEIKH, Professor of Internal Medicine, Faculty of Medicine, Tanta University, and All her staff members for helping me in the collection of the patients of this work.

I am deeply indebted to \mathcal{D}_{v} . OSAMA MOHAMED IBRAHIM, Assistant Professor and Chairman, Dept. of Clinical Pharmacy, Faculty of Pharmacy, Tanta, University for his continuous guidance, unlimited help, the precious time and effort he devoted in the supervision of the present work and for his kind support and cooperation.

I would like to express my sincere thanks and deepest gratitude to \mathcal{D}_t . HODA ABDEL-KADER EL-BAHRAWY, Assistant Professor and Chairman, Dept. of Biochemistry, Faculty of Pharmacy, Tanta University, for her encouragement, sustained support, expert guidance, valuable instructions and suggestions throughout this work. I feel to her much respect and I give her my warmest thanks.

My heartful thanks to all the STAFF MEMBERS of Clinical Pharmacy, Department, Janta University, for their kind support and cooperation.

I would like to express my sincere thanks and deepest gratitude to Eva Pharma & Amoun Pharmaceuticals for their help & sustained support during the work.



This thesis has been approved by the examination committee

for fair Prof. Dr. Fayza Lashin.

Prof. and Head of Internal Medicine Department, Faculty of Medicine, Tanta University

"Frof. Dr. Ahmed Fahmy Ahmed.

Prof. and Head of Pharmacology and Toxicology Department, Faculty of Pharmacy, Zagazeg University.

Prof. Dr. Wagih M. Awara. Wageh Hwan

Prof. of Pharmacology and Toxicology and Vice Dean Faculty of Pharmacy, Tanta University

Dr. Osama M. Ibrahim O Sama M. Ibra

Assistant Prof. and Head of Clinical Pharmacy Department, Faculty of Pharmacy,

Tanta University

Date: September 8, 2003

CONTENTS

	Page
INTRODUCTION	1
AIM OF THE WORK	2
REVIEW OF LITERATURE	3
Diabetes mellitus	3
• Insulin	15
Metabolic changes in diabetes	20
• Chromium	36
Oxidative stress	42
Alpha lipoic acid	45
Fibrinolytic system and diabetes	51
PATIENTS AND METHODS	55
RESULTS	81
DISCUSSION	110
SUMMARY AND CONCLUSIONS	128
REFERENCES -	132
ARABIC SUMMARY	

LIST OF TABLES

		Page
Table No		
1	Criteria for the diagnosis of diabetes mellitus and impaired glucose homeostasis.	23
2	The ideal ranges of the all lipid profile components	27
3	Chronic complications of diabetes mellitus.	30
4	Patient Charactersitics	82
5	The fasting blood glucose levels (mg/dL) of the diabetic patients in the different studied groups.	84
6	The postprandial blood glucose levels (mg/dL) of the diabetic patients in the different studied groups	86
7	The glycated hemoglobin (HbA ₁ c) levels (mg%) of the diabetic patients in the different studied groups	89
8	The total cholesterol levels (mg/dL) of the diabetic patients in the different studied groups.	93
9	The serum levels of HDL-Cholesterol (mg/dL) of the diabetic patients in the different studied groups.	95
10	The serum levels of LDL-Cholesterol (mg/dL) of the diabetic patients in the different studied groups	97
11	The serum levels of triglycerides (mg/dL) of the diabetic patients in the different studied groups	99
12	Malondialdehyde (MDA) levels (nmol/mL) in the sera of the diabetic patients in the different studied groups	102
13	The plasminogen activator inhibitor -1 (PAI-1) levels (ng/mL) of the diabetic patients in the different studied groups	105
14	The chromium levels (µg/L) in the different studied groups in the sera of the diabetic patients in the different studied groups	108

LIST OF FIGURES

Pag	e
Figure (1): Associations between insulin resistance, hyperinsulinaemia and	
promotion of atherosclerosis	3
Figure (2): Structure of human insulin.	6
Figure (3): The manufacture and release of insulin from the β-cell	6
Figure (4): The insulin receptor	7
Figure (5): Dose-response curves for the production and utilization of	
glucose1	8
Figure (6): The Effects of severe insulin deficiency on body fuel	
metabolism22	2
Figure (7): Proposed mechanism of action of chromium on insulin	
receptor	1
Figure (8): Hyperglycemia induced oxidative stress.	4
Figure (9): Oxidized and reduced forms of alpha lipoic acid	5
Figure (10): The role of ALA in regenerating vitamin C and vitamin E	
Figure (11): Overview of the fibrinolytic pathways	1
Figure(12):Standard curve of malonedialdehyde	2
Figure (13): Standard curve of plasminogen activator inhibitor type-1(PAI-1) 7'	7
Figure(14): Standard curve of serum chromium	
Figure (15):Fasting blood glucose levels in all studied diabetic groups before	
and after treatment.	5
Figure (16): Postprandial blood glucose levels in all studied diabetic groups	9
before and after treatment	7
Figure (17):Blood glycated hemoglobin levels in all studied diabetic groups	
before and after treatment	0
Figure (18): Serum total cholestrol levels in all studied diabetic groups before	_
and after treatment 94	4
Figure (19): Serum high density lipoprotien-cholesterol in all studied diabetic	(6)
groups before and after treatment.	6

Figure (20): Serum low density lipoprotien-cholesterol in all studied diabetic	
groups before and after treatment	98
Figure (21): Serum triglyceride levels in all studied diabetic groups before and	
after treatment	100
Figure (22): Serum malonedialdehyde in all studied diabetic groups before and	
after treatment	103
Figure (23): The levels of plasminogen activator inhibitor type -1	
in all studied diabetic groups before and after treatment	106
Figure (24): Serum chromium in all studied diabetic groups before and after	
treatment	109

LIST OF ABBREVIATIONS

ADP Adenosine-5-diphosphate.

AGEs Advanced glycosylation end products.

ALA Alpha Lipoic acid.

ATP Adenosine-5-triphosphate.

BMI Body mass index.

Bovine serum albumin. BSA CE Cholesterol esterase.

Cholesterol oxidase. $C_{\rm ox}$

Cr Chromium.

DAP Dihydroxy acetone phosphate.

DHLA Dihydrolipoic acid. DKA Diabetic ketoacidosis. DM Diabetes mellitus

EBF Endoneurial blood flow.

EDTA Ethylene diamine tetra acetic acid.

ESADDI Estimated safe and adequate daily dietary

intake.

ETA-AAS Electrothermal atomic absorption.

FPG Fasting plasma glucose. **GDM** Gestational diabetes mellitus.

GK Glycerol Kinase.

GLUT-1 Glucose transporter type 1. GLUT-4 Glucose transporter type 4. G-3-P Glycerol-3-phosphate.

GPO Glyceryl phosphate oxidase. **GTF** Glucose tolerance factor. HbA1a Glycated hemoglobin type a. HbA1a₂ Glycated hemoglobin type a₂.

HbA1b Glycated hemoglobin type b. HbA1c Glycated hemoglobin type c. HbAo Non-glycosylated hemoglobin

High density lipoprotein. HDL

HLA Human leukocyte antigen.